Doxorubicin Gastric Cancer Analysis and Forecast to

We are sorry but this premium report expired!

This market research, not available anymore on the publisher's website, was withdrawn from our database.

To get an alternative report, you can either :

  • Have a look at the list of documents hereafter
  • Launch a new search below

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

DOWNLOAD THESE REPORTS NOW!

Cardio Incorporated SWOT Analysis, Strategy, Revenues and Profits

Cardio Incorporated SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 15 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. SWOT Analysis report provides you a strategic analysis and detailed ...

Industries: Pathology | Countries: Japan

Ina Research Inc. (Symbol:2176) SWOT Analysis, Strategy, Revenues and Profits

Ina Research Inc. (Symbol:2176) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Ina Research Inc. SWOT Analysis report provides you a strategic analysis ...

Industries: Pathology | Countries: Philippines, Japan

Chemed Corporation (Symbol:CHE) SWOT Analysis, Strategy, Revenues and Profits

Chemed Corporation (Symbol:CHE) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Chemed Corporation SWOT Analysis report provides you a strategic analysis ...

Industries: Pathology | Countries: United States, Philippines, Singapore, Indonesia, Mexico, Japan, China

TOA EIYO LTD. SWOT Analysis, Strategy, Revenues and Profits

TOA EIYO LTD. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 15 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. SWOT Analysis report provides you a strategic analysis and detailed ...

Industries: Pathology | Countries: Japan

BML Inc. (Symbol:4694) SWOT Analysis, Strategy, Revenues and Profits

BML Inc. (Symbol:4694) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. BML Inc. SWOT Analysis report provides you a strategic analysis and ...

Industries: Pathology | Countries: Japan

Sanwa Kagaku Kenkyusho Co., Ltd. - Strategic SWOT Analysis Review

Sanwa Kagaku Kenkyusho Co., Ltd. - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 15 pages

Summary Sanwa Kagaku Kenkyusho Co., Ltd. (Sanwa Kagaku) is a pharmaceutical company. The company manufactures and markets pharmaceuticals, diagnostics, medical and nursing care nutritionals and healthcare products. Its products include SK-0403, SK-1202 and SK-1211. Sanwa Kagaku's SK-0403 is an oral hypoglycemic ...

Industries: Pathology | Countries: Japan

Eisai GmbH SWOT Analysis, Strategy, Revenues and Profits

Eisai GmbH SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 15 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. SWOT Analysis report provides you a strategic analysis and detailed ...

Industries: Pathology | Countries: Europe, Germany, Switzerland, Netherlands, United States, Sweden, Spain, Slovakia (slovak Republic), Russian Federation, Portugal, Norway, Italy, Ireland, France, Finland, Denmark, Austria, Japan, World

Teijin Pharma Limited SWOT Analysis, Strategy, Revenues and Profits

Teijin Pharma Limited SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 15 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. SWOT Analysis report provides you a strategic analysis and detailed ...

Industries: Pathology | Countries: Japan

UMN Pharma Inc. (4584) - Financial and Strategic SWOT Analysis Review

UMN Pharma Inc. (4584) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

Summary UMN Pharma Inc. (UMN) is a biopharmaceutical company. The company develops vaccines to cure diabetes, muscular dystrophy and influenza. Its products include UMN-0502, UMN-0501, UMN-0901 and UMN-2003. UMN's UMN-0502 is seasonal influenza vaccine. The company's UMN-0501 and UMN-0901 are pandemic ...

Industries: Pathology | Countries: Japan

GNI Group Ltd. (2160) - Financial and Strategic SWOT Analysis Review

GNI Group Ltd. (2160) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

Summary GNI Group Ltd. (GNI) is a biopharmaceutical company. The company discovers, develops and manufactures therapeutic drug candidates for the treatment of cancer and inflammatory disease. Its products include F647, F351, and F573. GNI's F647 is an anti inflammatory small molecule compound designed ...

Industries: Pathology | Countries: Japan

24/7 Customer Service

You can call our customer service 24 hours a day / 7 days a week

  • +1 718 303 2019

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.